Publish additional data and detail from the GeneSight study
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 6 Nov 2023
- Due
- 31 Dec 2024
- Delivered
- July 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Additional data and detail from this study is expected to be published in 2024.”
What we found
Evidence strength B What the grades mean
GeneSight study data was published in the Journal of Clinical Psychopharmacology in July 2025, after the 2024 deadline.
-
B Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
“Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical Psychopharmacology has published a study” ✓ confirmed on the page
-
D Myriad Genetics Research Shows Reduction in Percent of MDD Patients with Hospitalizations after GeneSight Testing
“Published: June 8, 2024” ✓ confirmed on the page
-
D Real-World Impact of Pharmacogenomic Testing on Medication Use and Healthcare Resource Utilization in Patients With Major Depressive Disorder
“Received November 8, 2024; accepted after revision February 2, 2025.”
Checked 6 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Publish
- Deliverable
- GeneSight study data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Myriad Genetics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-MYGN-003926 · Corrections policy